Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial
| العنوان: | Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial |
|---|---|
| المؤلفون: | Xiuying Zhang, Huahui Ren, Cuiling Zhao, Zhun Shi, Li Qiu, Fangming Yang, Xianghai Zhou, Xueyao Han, Kui Wu, Huanzi Zhong, Yufeng Li, Junhua Li, Linong Ji |
| المصدر: | Zhang, X, Ren, H, Zhao, C, Shi, Z, Qiu, L, Yang, F, Zhou, X, Han, X, Wu, K, Zhong, H, Li, Y, Li, J & Ji, L 2022, ' Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes : a 6 month, two-arm randomised trial ', Diabetologia, vol. 65, no. 11, pp. 1613-1626 . https://doi.org/10.1007/s00125-022-05768-5Test |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Blood Glucose, Vildagliptin, China, Research, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Gut microbiota, Gastrointestinal Microbiome, Gastrointestinal Tract, Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Internal Medicine, Humans, Hypoglycemic Agents, Acarbose, Glucose-lowering drugs, Ecosystem, Glipizide |
| الوصف: | Aims/hypothesis The use of oral glucose-lowering drugs, particularly those designed to target the gut ecosystem, is often observed in association with altered gut microbial composition or functional capacity in individuals with type 2 diabetes. The gut microbiota, in turn, plays crucial roles in the modulation of drug efficacy. We aimed to assess the impacts of acarbose and vildagliptin on human gut microbiota and the relationships between pre-treatment gut microbiota and therapeutic responses. Methods This was a randomised, open-labelled, two-arm trial in treatment-naive type 2 diabetes patients conducted in Beijing between December 2016 and December 2017. One hundred participants with overweight/obesity and newly diagnosed type 2 diabetes were recruited from the Pinggu Hospital and randomly assigned to the acarbose (n=50) or vildagliptin (n=50) group using sealed envelopes. The treatment period was 6 months. Blood, faecal samples and visceral fat data from computed tomography images were collected before and after treatments to measure therapeutic outcomes and gut microbiota. Metagenomic datasets from a previous type 2 diabetes cohort receiving acarbose or glipizide for 3 months were downloaded and processed. Statistical analyses were applied to identify the treatment-related changes in clinical variables, gut microbiota and associations. Results Ninety-two participants were analysed. After 6 months of acarbose (n=44) or vildagliptin (n=48) monotherapy, both groups achieved significant reductions in HbA1c (from 60 to 46 mmol/mol [from 7.65% to 6.40%] in the acarbose group and from 59 to 44 mmol/mol [from 7.55% to 6.20%] in the vildagliptin group) and visceral fat areas (all adjusted p values for pre–post comparisons Bacteroidetes species. Three months and 6 months of acarbose-induced changes in microbial composition were highly similar in type 2 diabetes patients from the two independent studies. Vildagliptin treatment significantly enhanced fasting active glucagon-like peptide-1 (GLP-1) levels. Baseline gut microbiota, rather than baseline GLP-1 levels, were strongly associated with GLP-1 response to vildagliptin, and to a lesser extent with GLP-1 response to acarbose. Conclusions/interpretation This study reveals common microbial responses in type 2 diabetes patients treated with two glucose-lowering drugs targeting the gut differently and acceptable performance of baseline gut microbiota in classifying individuals with different GLP-1 responses to vildagliptin. Our findings highlight bidirectional interactions between gut microbiota and glucose-lowering drugs. Trial registration ClinicalTrials.gov NCT02999841 Funding National Key Research and Development Project: 2016YFC1304901. Graphical abstract |
| وصف الملف: | application/pdf |
| تدمد: | 1432-0428 0012-186X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cb607520dfee7de88ca6f2725e4de5Test https://doi.org/10.1007/s00125-022-05768-5Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....29cb607520dfee7de88ca6f2725e4de5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14320428 0012186X |
|---|